Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD).

Abstract

Introduction: Given the high rate of primary and acquired resistance to current inflammatory bowel disease (IBD) treatments, novel drug targets and biomarkers that aid in therapeutic prediction are eagerly awaited. Furthermore, postponing treatment initiation because of a diagnostic delay profoundly affects patient well-being and overall disease evolution. Among the emerging targets and biomarkers, oncostatin M (OSM) has gained much interest in the past few years.Areas covered: A literature search to June 2019 was performed to identify the most relevant reports on Oncostatin M. The authors summarize the biology of OSM, its role in health and disease, its potential as a diagnostic, prognostic and therapeutic biomarker in the field of IBD and how it might be a drug target of the future.Expert opinion: OSM has diagnostic, prognostic and therapeutic capabilities. High mucosal OSM predicts primary non-response to anti-TNF antibodies. However, one could question whether a single cytokine can capture the complexity and heterogeneity of IBD. Neutralizing OSM in patients with elevated mucosal OSM appears to be attractive and should be considered as a valid option for the first biomarker-stratified, proof-of-concept trial that studies a novel therapeutic compound in IBD.

• Authors: Sare Verstockt, Bram Verstockt, Séverine Vermeire
• Journal: Expert opinion on therapeutic targets (Expert Opin Ther Targets) Vol. 23 Issue 11 Pg. 943-954 (11 2019) ISSN: 1744-7631 [Electronic] England
• PMID: 31587593 (Publication Type: Journal Article, Review)

Chemical References

• Biomarkers
• Oncostatin M

Topics

• Animals
• Biomarkers (metabolism)
• Humans
• Inflammatory Bowel Diseases (diagnosis, physiopathology, therapy)
• Oncostatin M (metabolism)
• Prognosis